Contact SCGE
Your email
Message
Send
SCGE Consortium Home
|
About SCGE TCDC
|
Contact Us
|
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
NCTID
NCT05197270
(View at clinicaltrials.gov)
Description
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
(Show More)
Indication
Neovascular (Wet) Age-Related Macular Degeneration
Compound Name
4D-150
Sponsor
4D Molecular Therapeutics
Funder Type
Industry
Status
Recruiting
Enrollment Count
215
Therapy Information
Target Gene/Variant
Anti-VEGF
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Genetic delivery of therapeutic protein
Route of Administration
Intravitreal
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
AAV
Editor Type
none
Dose 1
1E10 vg/eye
Dose 2
3E10 vg/eye (planned phase 3 dose)
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase1, Phase2
Submit Date
2022-01-05
Completion Date
2026-11
Last Update
2024-11-05
Participation Criteria
Eligible Age
>=50 Years
Standard Ages
Adult, Older adult
Eligible Sex
ALL
Locations
No.of Trial Sites
24
Locations
Puerto Rico,United States
Regulatory Information
Has US IND
True
Recent Updates
Phase III trial to begin Q1 2025
Resources/Links
Clinical Publications
(Corporate Presentation) Intravitreal 4D-150: Phase 2 Population Extension in Broad Disease Activity Wet AMD Patients - July 2024
(Corporate Presentation) 4D-150: PRISM Phase 2b 52-week Topline Data in Wet AMD and Program Update - February 2025
News and Press Releases
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME